RU95114742A - PHARMACEUTICAL COMPOSITION, METHOD FOR ADMINISTRATION OF HEPIRON, ORAL MEDICINAL FORM - Google Patents

PHARMACEUTICAL COMPOSITION, METHOD FOR ADMINISTRATION OF HEPIRON, ORAL MEDICINAL FORM

Info

Publication number
RU95114742A
RU95114742A RU95114742/14A RU95114742A RU95114742A RU 95114742 A RU95114742 A RU 95114742A RU 95114742/14 A RU95114742/14 A RU 95114742/14A RU 95114742 A RU95114742 A RU 95114742A RU 95114742 A RU95114742 A RU 95114742A
Authority
RU
Russia
Prior art keywords
composition according
dosage form
gepirone
administration
oral
Prior art date
Application number
RU95114742/14A
Other languages
Russian (ru)
Other versions
RU2155044C2 (en
Inventor
Т.Дэвид Стефен
Е.Гальян Клод
С.Х.Чоу Джозеф
Original Assignee
Бристоль-Мейерз Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/301,281 external-priority patent/US5478572A/en
Application filed by Бристоль-Мейерз Сквибб Компани filed Critical Бристоль-Мейерз Сквибб Компани
Publication of RU95114742A publication Critical patent/RU95114742A/en
Application granted granted Critical
Publication of RU2155044C2 publication Critical patent/RU2155044C2/en

Links

Claims (16)

1. Фармацевтическая композиция для получения лекарственных форм гепирона длительного выделения, содержащая: (а) от 0,5 до 12,0 мас.% гидрохлорида гепирона, (б) от 70 до 85 мас.% фармацевтически приемлемой целлюлозной полимерной матрицы; (в) соответствующие количества одного или нескольких фармацевтически приемлемых наполнителей, отличающаяся тем, что скорость выделения гепирона иэ лекарственной формы такова, что для достижения поглощения от 90 до 95% гепирона требуется примерно 18 - 24 ч.1. A pharmaceutical composition for producing dosage forms of hepirone of prolonged release, comprising: (a) from 0.5 to 12.0 wt.% Hepiron hydrochloride, (b) from 70 to 85 wt.% Of a pharmaceutically acceptable cellulosic polymer matrix; (c) appropriate amounts of one or more pharmaceutically acceptable excipients, characterized in that the rate of release of gepirone and dosage form is such that it takes about 18 to 24 hours to reach 90 to 95% of the gepirone. 2. Композиция по п. 1, отличающаяся тем, что (в) включает по крайней мере один из красителей, микрокристаллическую целлюлозу, колоидальный диоксид кремния и стеарат магния. 2. The composition according to p. 1, characterized in that (c) includes at least one of the dyes, microcrystalline cellulose, colloidal silicon dioxide and magnesium stearate. 3. Композиция по п. 2, отличающаяся тем, что (б) представляет оксипропилметилцеллюлозу, имеющую вязкость примерно от 15000 сантипуаз до примерно 100000 сантипуаз. 3. The composition according to p. 2, characterized in that (b) represents hydroxypropyl methylcellulose having a viscosity of from about 15,000 centipoise to about 100,000 centipoise. 4. Композиция по п. З, отличающаяся тем, что она по существу состоит из: (а) от 0,5 до 11,0 мас.% гидрохлорида гепирона; (б) от 72,0 до 83,0 мас.% гидроксипропилметилцеллюлозы; в) от 0,1 до 0,7% красителей; (г) от 10,0 до 20,0% микрокристаллической целлюлозы; (д) от 0,3 до 0,6% коллоидального диоксида кремния; и (е) от 0,3 до примерно 1,0% стеарата магния. 4. The composition according to p. 3, characterized in that it essentially consists of: (a) from 0.5 to 11.0 wt.% Hepiron hydrochloride; (b) from 72.0 to 83.0 wt.% hydroxypropyl methylcellulose; c) from 0.1 to 0.7% of dyes; (g) from 10.0 to 20.0% microcrystalline cellulose; (e) from 0.3 to 0.6% colloidal silicon dioxide; and (e) from 0.3 to about 1.0% magnesium stearate. 5. Композиция по п. 4, отличающаяся тем, что она содержит: (а) 5,3 мас. % гидрохлорида гепирона; (б) 77,3 оксипропилметилцеллюлозы, имеющей вязкость около 100000 сантипуаз; (в) от 0,1 до 0,2% пигмента на основе оксида железа; (г) 16,5% микрокристаллической целлюлозы; (д) 0,4% коллоидального диоксида кремния; и (е) 0,3% стеарата магния. 5. The composition according to p. 4, characterized in that it contains: (a) 5.3 wt. % gepirone hydrochloride; (b) 77.3 hydroxypropyl methylcellulose having a viscosity of about 100,000 centipoise; (c) from 0.1 to 0.2% pigment based on iron oxide; (g) 16.5% microcrystalline cellulose; (e) 0.4% colloidal silicon dioxide; and (e) 0.3% magnesium stearate. 6. Оральная лекарственная форма, отличающаяся тем, что содержит фармацевтическую композицию по п. 5. 6. An oral dosage form, characterized in that it contains the pharmaceutical composition according to claim 5. 7. Композиция по п. 4, отличающаяся тем, что она содержит: (а) 2,7 мас. % гидрохлорида гепирона; (6) 80,0% оксипропилметилцеллюлозы, имеющей вязкость около 100000 сантипуаз; (в) от 0,6 до 0,9% красителей, (г) 0,4% коллоидального диоксида кремния; и (д) 0,3% стеарата магния. 7. The composition according to p. 4, characterized in that it contains: (a) 2.7 wt. % gepirone hydrochloride; (6) 80.0% hydroxypropyl methylcellulose having a viscosity of about 100,000 centipoise; (c) from 0.6 to 0.9% of dyes; (d) 0.4% of colloidal silicon dioxide; and (e) 0.3% magnesium stearate. 8. Оральная лекарственная форма, отличающаяся тем, что она содержит композицию по п. 7. 8. An oral dosage form, characterized in that it contains a composition according to claim 7. 9. Способ введения гепирона, отличающийся тем, что состоит в оральном введении лекарственной формы, приготовленной из композиции по п. 1. 9. The method of administration of gepirone, characterized in that it consists in the oral administration of a dosage form prepared from a composition according to claim 1. 10. Способ введения гепирона, отличающийся тем, что он состоит в оральном введении лекарственной формы, приготовленной из композиции по п. 5. 10. The method of administration of gepirone, characterized in that it consists in the oral administration of a dosage form prepared from a composition according to claim 5. 11. Способ введения гепирона, отличающийся тем, что он состоит в оральном введении лекарственной формы, приготовленной из композиции по п. 7. 11. The method of administration of gepirone, characterized in that it consists in the oral administration of a dosage form prepared from a composition according to claim 7. 12. Лекарственная форма, отличающаяся тем, что она включает микрогранулы композиции по п.1, причем микрогранулы таблетированы или помещены в капсулы. 12. A dosage form, characterized in that it includes microgranules of the composition according to claim 1, wherein the microgranules are tabletted or placed in capsules. 13. Лекарственная форма по п. 12, отличающаяся тем, что микрогранулы покрыты фармацевтически приемлемым веществом, образующим покрытие. 13. A dosage form according to claim 12, characterized in that the microgranules are coated with a pharmaceutically acceptable coating forming material. 14. Оральная лекарственная форма, отличающаяся тем, что она включает таблетки прямого прессования композиции по п. 1. 14. An oral dosage form, characterized in that it comprises tablets of direct compression of the composition according to claim 1. 15. Оральная лекарственная форма, отличающаяся тем, что она включает таблетки прямого прессования композиции по п. 5. 15. Oral dosage form, characterized in that it includes tablets of direct compression of the composition according to p. 5. 16. Оральная лекарственная форма, отличающаяся тем, что она включает таблетки прямого прессования композиции по п. 7. 16. An oral dosage form, characterized in that it comprises tablets of direct compression of the composition according to claim 7.
RU95114742/14A 1994-09-06 1995-09-05 Pharmaceutical composition, method of hepiron administration, oral medicinal form RU2155044C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US301,281 1994-09-06
US08/301,281 US5478572A (en) 1994-09-06 1994-09-06 Gepirone dosage form

Publications (2)

Publication Number Publication Date
RU95114742A true RU95114742A (en) 1997-12-10
RU2155044C2 RU2155044C2 (en) 2000-08-27

Family

ID=23162703

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95114742/14A RU2155044C2 (en) 1994-09-06 1995-09-05 Pharmaceutical composition, method of hepiron administration, oral medicinal form

Country Status (25)

Country Link
US (1) US5478572A (en)
EP (1) EP0700680B1 (en)
JP (1) JP4540756B2 (en)
KR (1) KR100380806B1 (en)
CN (1) CN1096858C (en)
AT (1) ATE186462T1 (en)
AU (1) AU702282B2 (en)
CA (1) CA2157323C (en)
CY (1) CY2222B1 (en)
CZ (1) CZ286417B6 (en)
DE (1) DE69513254T2 (en)
DK (1) DK0700680T3 (en)
ES (1) ES2142432T3 (en)
FI (1) FI117319B (en)
GR (1) GR3032598T3 (en)
HK (1) HK1014666A1 (en)
HU (1) HU227339B1 (en)
IL (1) IL114984A (en)
NO (1) NO307814B1 (en)
NZ (1) NZ272855A (en)
PL (1) PL180691B1 (en)
RU (1) RU2155044C2 (en)
SG (1) SG30436A1 (en)
TW (1) TW445152B (en)
ZA (1) ZA957144B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060068017A1 (en) * 1996-03-25 2006-03-30 Wyeth Extended release formulation
US20030215507A1 (en) * 1996-03-25 2003-11-20 Wyeth Extended release formulation
US20040023948A1 (en) * 1997-03-24 2004-02-05 Green Richard David Fast-dispersing dosage form containing 5-HT1 agonists
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
US5895663A (en) * 1997-07-31 1999-04-20 L. Perrigo Company Pseudoephedrine hydrochloride extended-release tablets
CN100367965C (en) * 1999-12-20 2008-02-13 法布瑞-克雷默制药有限公司 Use of bioactive metabolites of gepirone for the treatment of psychological disorders
US6534507B1 (en) * 1999-12-20 2003-03-18 Fabre-Kramer Pharmaceuticals, Inc. Methods for treating psychological disorders using bioactive metabolites of gepirone
CN1479620A (en) * 2000-12-08 2004-03-03 ��˹��ŵ�� Oral extended release formulation of gepirone
CZ20032959A3 (en) * 2001-05-01 2004-01-14 Pfizer Products Inc. Process for preparing a pharmaceutical composition with low dosage of a medicament and having uniform distribution and efficiency of the medicament
PE20030527A1 (en) * 2001-10-24 2003-07-26 Gruenenthal Chemie DELAYED-RELEASE PHARMACEUTICAL FORMULATION CONTAINING 3- (3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL) PHENOL OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME AND ORAL TABLETS CONTAINING IT
US20030152621A1 (en) * 2001-11-21 2003-08-14 Egberink J. G. J. Pharmaceutical formulation of gepirone for oral administration
TW200306866A (en) * 2002-05-07 2003-12-01 Akzo Nobel Nv A method to improve surface properties of pharmaceutical tablets
AU2003274110A1 (en) * 2002-09-24 2004-04-19 Akzo Nobel N.V. Method to improve pharmaceutical tablets having a matrix of cellulose ether
CN1819821B (en) 2003-08-08 2010-10-13 拜奥维尔实验室国际股份有限公司 Modified-release tablet of bupropion hydrochloride
AR048112A1 (en) * 2004-03-25 2006-03-29 Solvay Pharm Bv DERIVATIVES OF 1- (2H-1-BENZOPIRAN-2-ON-8-IL) -PIPERAZINE FOR PAIN TREATMENT
AR049478A1 (en) * 2004-03-25 2006-08-09 Solvay Pharm Bv A PROCEDURE FOR THE PREPARATION OF 3-AMINO-8- (1-PIPERAZINIL) -2H-1-BENZOPIRAN-2-ONA. SALTS AND HYDRATES AND PHARMACEUTICAL COMPOSITIONS.
US7799273B2 (en) 2004-05-06 2010-09-21 Smp Logic Systems Llc Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes
US7444197B2 (en) 2004-05-06 2008-10-28 Smp Logic Systems Llc Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
US20060013874A1 (en) * 2004-07-15 2006-01-19 Solvay Pharmaceuticals B.V. Extended release formulation of 3-amino-8-(1-piperazinyl)-2H-1-benzopyran-2-one
PL1781292T3 (en) * 2004-07-15 2011-03-31 Abbott Healthcare Products Bv Extended release formulation of 3-amino-8-(1-piperazinyl)-2h-1benzopyran-2-one
JP2008519071A (en) * 2004-11-05 2008-06-05 ファーブル−クレイマー・ホールディングス・インコーポレイテッド High-dose sustained-release formulation of gepirone
US20060099267A1 (en) * 2004-11-05 2006-05-11 Fabre-Kramer Pharmaceuticals, Inc. High-dosage extended-release formulation of gepirone
EP1888080B1 (en) * 2005-06-09 2010-04-14 Euro-Celtique S.A. Pharmaceutical compositions of a neuroactive steroid and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
GB1405088A (en) * 1971-06-03 1975-09-03 Mundipharma Ag Slow release formulation
US3965256A (en) * 1972-05-16 1976-06-22 Synergistics Slow release pharmaceutical compositions
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
US4357469A (en) * 1979-06-14 1982-11-02 Forest Laboratories, Inc. Carrier base material for prolonged release therapeutic compositions
US4248856A (en) * 1979-07-10 1981-02-03 American Home Products Corporation Sustained release pharmaceutical compositions
US4309406A (en) * 1979-07-10 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4248858A (en) * 1979-08-09 1981-02-03 American Home Products Corporation Sustained release pharmaceutical compositions
US4547358A (en) * 1980-05-06 1985-10-15 Mead Johnson & Company Sustained release tablet containing at least 95 percent theophylline
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4423049A (en) * 1981-12-28 1983-12-27 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
US4704284A (en) * 1982-08-12 1987-11-03 Pfizer Inc. Long-acting matrix tablet formulations
US4690824A (en) * 1983-07-07 1987-09-01 Redi-Rowell, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range
US4610870A (en) * 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
US4695591A (en) * 1985-03-29 1987-09-22 Schering Corporation Controlled release dosage forms comprising hydroxypropylmethylcellulose
SE460947B (en) * 1986-08-26 1989-12-11 Lejus Medical Ab A MULTIPLE-UNIT DOS COMPOSITION OF L-DOPA
US4771053A (en) * 1987-03-02 1988-09-13 Bristol-Myers Company Method for alleviation of primary depressive disorders
US4782060A (en) * 1987-07-29 1988-11-01 Bristol-Myers Company Gepirone for alleviation of panic disorders
SE8703881D0 (en) * 1987-10-08 1987-10-08 Haessle Ab NEW PHARMACEUTICAL PREPARATION
SE8704097D0 (en) * 1987-10-22 1987-10-22 Astra Ab ORAL FORMULATION OF BUSPIRONE AND SALTS THEREOF
US5106849A (en) * 1988-05-24 1992-04-21 American Home Products Corporation Use of aryl- and heteroaryl piperazinyl carboxamides in the treatment of various central nervous system disorders
US5096908A (en) * 1990-05-04 1992-03-17 Eli Lilly And Company Method of inhibiting gastric acid secretion
US5189179A (en) * 1990-08-29 1993-02-23 Merrell Dow Pharmaceuticals Inc. Serotonin 5ht1a agonists
US5124346A (en) * 1991-04-23 1992-06-23 Pfizer Inc. Synergistic combinations in the treatment of anxiety
US5169638A (en) * 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
US5292766A (en) * 1992-03-25 1994-03-08 Eli Lilly And Company Method for improving primary memory and/or learning
US5378846A (en) * 1993-06-11 1995-01-03 Russian-American Institute For New Drug Development 1,2,3,4-tetrahydropyrrolo-[1,2-a]-pyrazine derivatives

Similar Documents

Publication Publication Date Title
RU95114742A (en) PHARMACEUTICAL COMPOSITION, METHOD FOR ADMINISTRATION OF HEPIRON, ORAL MEDICINAL FORM
AU736243B2 (en) Film coated tablet compositions having enhanced disintegration characteristics
JP2955524B2 (en) Solid drug preparation
US6177102B1 (en) Once daily analgesic tablet
AU719170B2 (en) Pharmaceutical compressed tablet characterized by a high increase in volume by contact with biological fluids
US6703044B1 (en) Venlafaxine formulations
US8252327B2 (en) Oral controlled release dosage form
US5861173A (en) Long-lasting release nifedipine preparation
US5859060A (en) Timed release tablet comprising naproxen and pseudoepherine
JPH061716A (en) Medical prescription having long-term releasability of active ingredient
ZA200309724B (en) Oral controlled release pharmaceutical composition for one a day therapy for the treatment and prophylaxis of cardiac and circulatory diseases
CA2392085A1 (en) Carvedilol methanesulfonate
US5814339A (en) Film coated tablet of paracetamol and domperidone
WO2009118763A1 (en) Multilayered pharmaceutical compositions and processes thereof
KR960010007A (en) Gephyron Dose Type
US4888343A (en) Pharmaceutical compositions for relief of dysmenorrhea and/or premenstrual syndrome and process
US6994871B2 (en) Once a day antihistamine and decongestant formulation
RU2001125667A (en) DIRECTLY PRESSED MATRIX FOR REGULATED RELEASE OF ONE-TIME DAILY DOSES OF CLARITROMYCIN
JPH05246845A (en) Antipyretic analgesic agent containing ibuprofen
CA2386547A1 (en) Orally disintegrating composition comprising mirtazapine
US5998478A (en) Timed release tablet comprising naproxen and pseudoephedrine
JPS6193113A (en) Durative preparation for oral cavity
CA2503380A1 (en) Pharmaceutical compositions containing venlafaxine
JPH03223211A (en) Three-layered tablet
US20070148241A1 (en) Use of an intermediate for controlling the release profile of an oral formulation of a medicament